Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

February 26-28, 2019
Hilton Tokyo Bay Hotel,
Tokyo, Japan

THE ONLY EVENT IN ASIA BRINGING TOGETHER SCIENCE, TECHNOLOGIES AND PARTNERS TO ACCELERATE OLIGONUCLEOTIDE AND PEPTIDE MOLECULES TO MARKET

Access the Science, Technologies and Partners You Need to Grow Your Business

Accelerate Your Product to Market

Hear case studies, best practices and lessons learned from global oligonucleotide and peptide developers currently in phase 2/3 clinical trials. Ensure product approval by hearing regulatory guidance and roadmaps to successful IND/IMPD submissions from industry leaders.

Evaluate New Technologies and Services

Improve your process development, analytical and manufacturing efforts by meeting with 20+ global technology leaders in the exhibit hall. The exhibit hall also features peer-submitted posters that contain new and unpublished research from global scientists working across all phases of oligonucleotide and peptide development.

Meet Your Next Partner at AsiaTIDES

Connect with 250+ oligonucleotide and peptide leaders across Asia, Europe and North America during networking lunches, dinners and cocktail receptions.

CROSS-FERTILIZE IDEAS AND BEST PRACTICES WITH RESEARCHERS FROM DIFFERENT DISCIPLINES

Oligonucleotide Track Highlights
  • Learn about advances in mRNA therapeutic development and CMC
  • Find new approaches to optimize oligonucleotide properties
  • Increase efficiency in oligonucleotide CMC and manufacturing
  • Overcome the delivery challenge by learning about new delivery technologies
  • Hear data from preclinical and clinical case studies with lessons learned
  • Pre-Conference Workshop: Accelerating Oligonucleotides to IND and Beyond
Peptide Track Highlights
  • Implement new approaches for peptide discovery and drug target identification
  • Discover the latest in peptide synthesis technologies and methods
  • Find new approaches to optimize peptide properties
  • Increase efficiency in peptide CMC and manufacturing
  • Hear data from preclinical and clinical case studies with lessons learned
  • Pre-Conference Workshop: Accelerating Peptides to IND: Moving to the Clinic, CMC and Beyond
NEW this year for 2019
  • mRNA therapeutics session featuring Moderna Therapeutics, BioNTech and CureVac
  • 1st Time Presenting Companies: WAVE, Stoke, CuroNZ, NapaJen, FunPep and more!
  • Expanded regulatory session for both peptides and oligonucleotides
  • More exhibitors and poster presentations than ever before

Get More From the Event - Add Pre-Conference Workshops To Your Registration

Workshop #1 - Accelerating Oligonucleotides to IND and Beyond

This workshop will address early drug development and CMC of oligonucleotide therapeutics. A detailed discussion of moving oligonucleotide therapeutics from discovery to clinical trials will include a description of strategies for early clinical development, including GMP synthesis, analytical controls and specifications; nonclinical, CMC, manufacturing and scale-up and the regulatory framework for preparation of IND-IMPD dossiers. Participants will also gain a basic understanding of the considerations and requirements for taking an oligonucleotide therapeutic into first-in-human clinical trials  

Speakers:

  • Marc M. Lemaitre, Ph.D., Principal, ML Consult, USA
  • Thomas Rupp, Owner & Principal, Thomas Rupp Consulting, Germany
Workshop #2 - Accelerating Peptides to IND: Moving to the Clinic, CMC and Beyond

This practical, introductory workshop will address early drug development of peptide therapeutics. A detailed discussion of moving peptide therapeutics from discovery to clinical trials will include a description of strategies for early clinical development, including GMP synthesis, analytical controls and specifications; formulation strategies; pharmacokinetics and toxicology study designs and requirements; and the regulatory framework for preparation of IND-IMPD dossiers. Participants will gain a basic understanding of the considerations and requirements for taking a peptide therapeutic into first-in-human clinical trials. 

Speakers:

  • Bruce Morimoto, Ph.D., Vice President, Drug Development-Operations, Alkahest, USA
  • Christopher Rhodes, Ph.D., President & CEO, Drug Delivery Experts, USA
  • Robert Hagopian, Director Business Development, PolyPeptide Group, USA
  • Duu-Gong Wu, Ph.D., Senior Director, Regulatory Consulting, PPD, USA

Meet the AsiaTIDES 2019 Scientific Advisory Board

  • Hiroaki Suga, Ph.D., Professor of Chemistry, School of Science, University of Tokyo, Japan 
  • Osamu Sato, Ph.D., General Manager, Sakigake-Projects; DS-5141 and DS-1647 and Senior Executive Advisor for Head of R&D, Daiichi Sankyo Co., Ltd., Japan
  • Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals 
  • James Thompson, Ph.D., Head of CMC Project Management, Moderna Therapeutics, Inc.
  • Daisuke Takahashi, Ph.D., Senior Principal Researcher, Bio-functional Molecular Chemistry Group, Research Institute for Bioscience Products & Fine Chemicals, Ajinomoto. Co., Inc., Japan
  • Hideaki Sato, President and CEO, Luxna Biotech, Japan
  • Robert Hagopian, Director Business Development, PolyPeptide Laboratories, USA
  • Dong-ki Lee, Ph.D., Professor, Sungkyunkwan University and CEO & Founder, OliX Pharmaceuticals, Korea
  • Shawn Lee, Ph.D., President and CEO, CPC Scientific, USA and China 
  • Patrick Lu, Ph.D., Founder, President and CEO, Sirnaomics, Inc., USA 
  • Michael McGinley, Global Technical Manager, Phenomenex, USA
  • Bruce Morimoto, Ph.D., Vice President, Drug Development-Operations, Alkahest, USA
  • El Djouhar Reka├», Head of Peptide Products Operation, PolyPeptide Group, Belgium
  • Susan Srivatsa, Ph.D., President, ElixinPharma, USA 
  • Dmitry Samarsky, Ph.D., Chief Technology Officer, Sirnaomics, USA
  • Mimoun Ayoub, Ph.D., Director and Head of North American and Emerging Markets, CordenPharma International, Switzerland

PARTNERING OPPORTUNITIES FOR ASIATIDES 2019


Meet the People Behind the Products and Get the Answers You Need

Highlight your company's expertise to 300+ Oligo and Peptide Decision Makers working across peptide & oligonucleotide development.  For pricing and package options, please contact:

Perri Lucatello
Perri.Lucatello@knect365.com 
+44 (0)20 7017 7247